Reply  by Makaroun, Michel S.
LETTERS TO THE EDITOR
Regarding “A randomized trial of carotid artery
stenting with and without cerebral protection”
We read with interest the report from the randomized trial of
carotid artery stenting (CAS) with and without cerebral protection
(CP), by Barbato et al. In this article, the authors aimed to test the
hypothesis that the use of filter protection would decrease the
percentage of cerebral embolic events, but at the end they reported
a relatively high complication rate for both randomized groups
(stroke at 30 days  11%).
Although CAS has developed rapidly over the last decade as a
minimally invasive alternative to carotid endarterectomy (CEA),
the optimal carotid revascularization strategy still remains a con-
troversial issue, and articles like this can prompt debate.
While we believe that the utility of CP does not need to be
demonstrated by a randomized trial, in our opinion, the way that
this trial was designedmeant that it could not effectively investigate
the value of filters. In order to study what really happens with or
without CP, the study design should have used transcranial Dopp-
ler to analyze the number of hits that occurred during the advance-
ment and deployment of the stent and the post-dilatation maneu-
vers in the unprotected group, as well as during the filter
deployment and retrieval maneuvers in the protected group.
By analyzing the occurrence of new embolic lesions by diffusion-
weighted magnetic resonance imaging (DW-MRI) 24 hours after
stenting, the authors did not focus on whether the events occurred
during the procedure (in any phase ofCAS: archmaneuvers, common
carotid engagement, stenting, ballooning, etc.) or later in the clinical
course. They even neglected to specify whether the four strokes were
intra- or post-procedural complications. Did these neurological
events occur during the arch maneuvers for carotid engagement1 (as
the cerebral contralateral lesions shown in 19%of patients atDWMRI
would seem to reveal) or in the early post-operative period? Both
hypotheses make it difficult to blame the use or non-use of CP.Many
microemboli can occur in the first hours after CAS and are probably
related to the composition of the treated plaque and to the scaffolding
property of the stent.2 In this study, no plaque characteristics were
reported and this could have distorted the results.
Another comment regards the low recruitment rate. Over two
years, only 35 patients were enrolled, while 225 patients (86.5%)
were excluded. What was the rate of patients who refused to give
consent to be randomized for a protected versus unprotected CAS?
Is the benefit of CP so intuitive as to be clear also to the
patients?
In conclusion, we agree with the authors that “the lack of
major strokes in the CP group may argue that at least large emboli
are captured” but their “numbers are too small to offer such a
reassuring statement,” however, we also think that these numbers
(without the exact timing of the complications and without related
plaque composition) are also too small to offer any definite state-
ment regarding the utility of CP.
Carlo Setacci, MD
Gianmarco de Donato, MD
Vascular and Endovascular Surgery Unit
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Reply
We readwith interest the letter to the editor fromDrDeDonato.
We certainly expected our study to be controversial and generate a
number of comments, because the value of filter cerebral protection
(CP) has been accepted as intuitivewith no reasonable justification for
any testing as the letter suggests. We disagree with that position,
because significant evidence suggests the opposite. As an example the
ARCHeR trial reported the lowest stroke rates in the first phase of the
study without any CP, with adverse events increasing with the intro-
ductionofCP in the second two arms, evenwith the added experience
of the operators.1 Themedical community has accepted the benefit of
filters without any discussion or evaluation, which has negatively
influenced the acceptance of patients to be enrolled in this trial as
suggested by the letter.
We differ significantly with the authors of the letter on whether
our trial design would have provided information about the value of
CP had the trial reached its target enrollment. A randomized trial is
the perfect vehicle for this determination, because all other confound-
ing factors would be expected to be equivalent between the two arms,
except forCP.The timingof thesemicroemboliwouldbe irrelevant in
a randomized trial design, because specifically the arch manipulation
and the postoperative events should be independent of CP and be
present to an equal degree between groups. Adding transcranial
doppler (TCD) evaluation to determine timing would have to be
extended for days, and the information is already available.Moreover,
the multitude of embolic signals on TCD does not necessarily equate
with brain tissue damage as DW MRI does. MacDonald2 did use
TCD in a study very similar to ourswithnearly identical results onDW
MRI; he also identified more hits during the procedure in patients
with CP. All the clinical events in our study occurred during the
procedure.
Since the development of our protocol in late 2002, many
patient and plaque characteristics have been identified to increase
the risk of carotid artery stenting (CAS), including age and plaque
composition but also arch anatomy, and more recently anatomic
characteristics of the lesion such as length and ostial location.3 We
stratified our randomization by symptomatic status, which is the
most significant predictor of adverse events known at the time, but
for obvious reasons not with all other factors identified since.
Although plaque echolucency has become of late a known predic-
tor of outcomes, it is also associated with symptomatic status that
was evenly randomized.
We have acknowledged that our study was underpowered and
does not offer conclusive proof as to the value or lack thereof of
CP. The study, however, does point to a possible downside of
filters, and a blanket insistence on their use in every case may be
detrimental to patient outcomes.
Michel S. Makaroun, MD
University of Pittsburgh
Pittsburgh, Pa
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Regarding “A randomized trial of carotid artery
stenting with and without cerebral protection”
Barbato and colleagues1 are to be congratulated on perform-
ing the first randomized trial comparing carotid artery stenting
(CAS) with and without the use of a filter-type cerebral protection
device. Although their results do not support the common notion
that cerebral protection devices reduce the number of embolic
events occurring during CAS, several points of concern arise with
respect to the conduct of the trial, patient selection and data
analysis.
On the basis of a retrospective analysis of non-randomized
data with all its inherent limitations, we recently demonstrated that
the use of protection devices significantly reduces the incidence of
new diffusion-weighted imaging (DWI) lesions after CAS (propor-
tion of patients with any new ipsilateral DWI lesion, 67% in those
treated without vs 49% in those treated with protection devices;
P  0.05) and that approximately 120 to 140 patients would be
needed for a randomized trial on the basis of these data.2 As already
pointed out by the authors, this trial therefore fell far short of a
sample size that would be sufficient to detect a significant differ-
ence between both treatment modalities. More importantly, sub-
group analyses of our data set have indicated that the beneficial
effect of protection devices in preventing the occurrence of new
DWI lesions might not pertain to older and asymptomatic pa-
tients.3 The negative findings of this trial could thus very well be
based on the high number of asymptomatic patients as well as old
patients. Along the way it should be noted that a minor or major
stroke rate of 13% in asymptomatic patients is unacceptably high,
indicating that the majority of patients included in this trial would
have been better off with medical treatment alone.
In the past few years, evidence has accumulated that certain
anatomic features, including a severe vessel tortuosity or aortic arch
abnormalities, are associated with an increased periprocedural
complication rate during CAS despite the use of cerebral protec-
tion devices.4,5 Despite the small patient number, a technical
failure rate of 11% in the cerebral protection group stresses the
importance of excluding these patients from any future trial.
Irrespective of these limitations, we definitely concur with
Barbato and colleagues that further randomized trials of unpro-
tected versus protected CAS using DWI as an additional surrogate
end point should be expedited. Ideally, these trials should include
only patients with a symptomatic carotid stenosis, who are younger
than 70 years of age.
Andreas Kastrup, MD
Sonja Schnaudigel, MD
Klaus Gröschel, MD
Department of Neurology
University of Göttingen
Göttingen, Germany
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Reply
We read with interest the thoughtful letter to the editor of
Kastrup et al and agree with most of the voiced comments, in
particular the recommendation that additional investigation of the
assumed salutory effects of distal protection filters should be un-
dertaken. Our study was significantly underpowered to answer the
question in a meaningful manner, and serves only to underscore
our lack of understanding of the potential drawbacks of routine
filter use during carotid artery stenting (CAS).
We are familiar with the authors’ study referred to in the letter,
showing findings quite different from ours in the frequency of
diffusion-weighted magnetic resonance imaging lesions among
patients treated with protected or unprotected CAS. We agree that
age and symptomatic status explain many of the differences be-
tween the two reports, but the retrospective studymethodology, as
well as the multitude of filters used with different crossing profiles
may have also influenced the findings. For example, their most
commonly used filter crosses the lesion as a simple wire, which may
be related to a lower incidence of noted microemboli. In addition,
the use of filters as well as the performance of magnetic resonance
imaging studies in their review did not follow specific indications,
introducing a selection bias that further complicates the compari-
son of our two studies.
Although we agree with Kastrup’s comments regarding the
lack of benefit of asymptomatic octogenarians from interventional
treatment in general and CAS in particular, care must be taken to
avoid the use of our clinical outcomes in a very limited dataset to
support or refute that contention. A larger review we previously
published agrees with the opinions presented in the letter.1 Our
current manuscript, however, which includes only a fraction of our
total experience, does not shed any additional light on the topic.
Michel S. Makaroun, MD
University of Pittsburgh
Pittsburgh, Pa
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Regarding “Aortic neck dilatation after endovascular
abdominal aortic aneurysm repair: A word of
caution”
Congratulations to Drs Diehm, Dick, Katzen, Schumidli,
Kalka, and Baumgartner for their review article focusing on the
phenomenon of neck dilation after endovascular abdominal aortic
aneurysm repair.1 However, this review did not include a study we
recently conducted and published in the Journal of Endovascular
Therapy.2 This study concludes with valuable results because it
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